The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr.
Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper ...
An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment ...
Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors ...
These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...
Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
Frank Lin reviews suprapubic versus urethral catheterization for neurogenic bladder patients unable to perform intermittent catheterization. Systematic review of over 2,000 patients showed comparable ...
Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2) A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN ...
Condition: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate Study ID: NCT07028853 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results